GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 August 2023 - 10:05AM
GeneDx, a leader in delivering improved health outcomes through
genomic and clinical insights, today announced that, effective as
of August 8, 2023, the compensation committee of GeneDx’s board of
directors granted newly-hired employees 23,769 restricted stock
units (“RSUs”) as inducements material to each employee entering
into employment with GeneDx. The RSUs were granted under GeneDx’s
2023 Equity Inducement Plan and in accordance with Nasdaq Listing
Rule 5635(c)(4).
The inducement RSUs will vest with respect to 25% of the
underlying shares on the first anniversary of July 21, 2023 (the
“Vesting Commencement Date”) and with respect to 6.25% of the
underlying shares on each of the 12 quarterly anniversaries of the
Vesting Commencement Date thereafter, subject to the employee’s
continued service with the Company on each applicable vesting
date.
About GeneDx
GeneDx (Nasdaq: WGS) delivers personalized and actionable health
insights to inform diagnosis, direct treatment and improve drug
discovery. The company is uniquely positioned to accelerate the use
of genomic and large-scale clinical information to enable precision
medicine as the standard of care. GeneDx is at the forefront of
transforming healthcare through its industry-leading exome and
genome testing and interpretation, fueled by one of the world’s
largest, rare disease data sets. For more information, please visit
www.genedx.com and connect with us on LinkedIn, Facebook, Twitter
and Instagram.
GeneDx Investor Relations Contact:Tricia
TruehartInvestors@GeneDx.com
GeneDx Media Contact:Maurissa MessierPress@GeneDx.com
GeneDx (NASDAQ:WGS)
Historical Stock Chart
From Apr 2024 to May 2024
GeneDx (NASDAQ:WGS)
Historical Stock Chart
From May 2023 to May 2024